NI201200085A - Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina - Google Patents

Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina

Info

Publication number
NI201200085A
NI201200085A NI201200085A NI201200085A NI201200085A NI 201200085 A NI201200085 A NI 201200085A NI 201200085 A NI201200085 A NI 201200085A NI 201200085 A NI201200085 A NI 201200085A NI 201200085 A NI201200085 A NI 201200085A
Authority
NI
Nicaragua
Prior art keywords
strescopin
heart failure
subject
treat heart
type peptides
Prior art date
Application number
NI201200085A
Other languages
English (en)
Inventor
P Shankley Nigel
N Sabbah Hani
J Gengo Peter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/612,548 external-priority patent/US10040838B2/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201200085A publication Critical patent/NI201200085A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevos métodos de tratamiento de la insuficiencia cardiaca que comprende administrar una cantidad de péptido tipo estrescopina a un sujeto que lo necesita; y mantener sustancialmente la cantidad de dicho péptido presente en el plasma de dicho sujeto en una concentración que resulta en un beneficio terapéutico sin un incremento sustancial en el ritmo cardíaco de dicho sujeto. El método implica el uso de péptidos tipo estrescopina que son antagonistas selectivos del receptor de hormonas de liberación de corticotrofina de tipo 2 (CRHR2).
NI201200085A 2009-11-04 2012-05-04 Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina NI201200085A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25818109P 2009-11-04 2009-11-04
US12/612,548 US10040838B2 (en) 2008-11-04 2009-11-04 CRHR2 peptide agonists and uses thereof

Publications (1)

Publication Number Publication Date
NI201200085A true NI201200085A (es) 2012-08-17

Family

ID=43926060

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200085A NI201200085A (es) 2009-11-04 2012-05-04 Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina

Country Status (15)

Country Link
US (1) US20110105397A1 (es)
EP (1) EP2496248A2 (es)
JP (1) JP2013510167A (es)
KR (1) KR20120103606A (es)
CN (1) CN102711801A (es)
AU (1) AU2010315131A1 (es)
BR (1) BR112012010661A2 (es)
CA (1) CA2780163A1 (es)
CO (1) CO6541617A2 (es)
EA (1) EA201290278A1 (es)
IL (1) IL219565A0 (es)
MX (1) MX2012005262A (es)
NI (1) NI201200085A (es)
PH (1) PH12012500895A1 (es)
WO (1) WO2011057027A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272151B (zh) * 2008-11-04 2014-08-20 詹森药业有限公司 Crhr2肽激动剂及其用途
CA2864100A1 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
AU2015242354A1 (en) * 2014-04-03 2016-11-10 The Regents Of The University Of California Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure
US20160161489A1 (en) * 2014-09-15 2016-06-09 Mark W. Linder Urine-based immuncassay for urocirtub 3 abd duagbisus if skeeo aobea
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
KR20190084055A (ko) * 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법
WO2018090042A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Methods of treating heart failure
WO2018090036A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Method of protection for cardiac tissue
US20250319161A1 (en) * 2021-03-17 2025-10-16 Cortene Inc. Improved methods of treating diseases resulting from a maladapted stress response
CN116217698B (zh) * 2023-03-28 2026-04-17 河南美森药业有限公司 一种血促性素提取纯化方法
WO2025184558A1 (en) 2024-02-28 2025-09-04 Caradon Therapeutics, Inc. Modified urocortin 3

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945515A3 (en) 1989-11-06 2002-08-21 Cell Genesys, Inc. Production of proteins using homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
IL154553A0 (en) * 2001-03-15 2003-09-17 Res Dev Foundation Urocortin-iii and uses thereof
AU2002310054B2 (en) 2001-05-21 2007-02-01 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
KR100512483B1 (ko) * 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2005035727A2 (en) * 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US20100249027A1 (en) * 2007-05-25 2010-09-30 William Henry Crf conjugates with extended half-lives
CN102272151B (zh) * 2008-11-04 2014-08-20 詹森药业有限公司 Crhr2肽激动剂及其用途

Also Published As

Publication number Publication date
CN102711801A (zh) 2012-10-03
WO2011057027A2 (en) 2011-05-12
PH12012500895A1 (en) 2012-11-12
EP2496248A2 (en) 2012-09-12
AU2010315131A1 (en) 2012-05-31
JP2013510167A (ja) 2013-03-21
KR20120103606A (ko) 2012-09-19
BR112012010661A2 (pt) 2016-11-22
US20110105397A1 (en) 2011-05-05
IL219565A0 (en) 2012-06-28
CA2780163A1 (en) 2011-05-12
CO6541617A2 (es) 2012-10-16
WO2011057027A3 (en) 2011-07-07
EA201290278A1 (ru) 2012-11-30
MX2012005262A (es) 2012-09-28

Similar Documents

Publication Publication Date Title
NI201200085A (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
PE20190205A1 (es) Uso de inhibidores de miostatina y terapias de combinacion
BR112013003823A2 (pt) conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
CL2011001578A1 (es) Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña.
MX2018010852A (es) Metodos para tratar la depresion con antagonistas del receptor de orexina-2.
EA201690606A1 (ru) Аналоги глюкагона
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
MX376077B (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
PE20140382A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
GT201700224A (es) Proteína de unión a rgma y su uso
MA32389B1 (fr) Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
CU24043B1 (es) Hormona foliculoestimulante humana recombinante, composición farmacéutica que la comprende
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
MX2018000657A (es) Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
CO6341479A2 (es) Péptidos agonistas de crhr2 y usos de estos
AR111380A1 (es) Tratamiento para el asma con anticuerpo anti-tslp